SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (2113)5/19/2004 10:44:25 AM
From: Icebrg  Read Replies (2) of 3044
 
Millennium Pharmaceuticals "neutral"

Wednesday, May 19, 2004 5:30:33 AM ET
Robert W. Baird

NEW YORK, May 19 (New Ratings) – Analysts at Robert W Baird reiterate their "neutral" rating on Millennium Pharmaceuticals (MLNM.NAS). The target price is set to $17.

Millennium Pharmaceuticals is a genomics driven healthcare company.

According to Robert W Baird’s research note published yesterday, Millennium Pharmaceuticals has announced that the phase III confirmatory study or the Apex trial of Velcade has revealed a survival advantage in relapsed multiple myeloma patients. The positive results were excepted after the approval of Velcade last year, based on the data from the phase II study of the drug’s SUMMIT trial, the analysts mention.

Millennium Pharmaceuticals is scheduled to provide the details of its Apex trial on June 6, at the ASCO meeting, according to Robert W Baird. The release of specific data on patients having only one prior treatment could result in the drug’s off-label use after the ASCO meeting, the analysts mention. The "neutral" rating reflects Millennium Pharmaceuticlas’ sluggish 1Q04 revenues and Velcade’s decelerated market momentum, the analysts add.

The EPS estimates for 2004 and 2005 are -$0.50 and -$0.33, respectively.

Robert W Baird reiterates its "neutral" rating on Millennium Pharmaceutical
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext